April 22, 2022
Life Sciences
  • The federal government has engaged in preliminary talks to buy Japanese drugmaker Shionogi & Co.’s experimental COVID-19 antiviral pill. Shionogi’s treatment is in late-stage clinical trials and hasn’t yet been authorized, but previous studies showed lowered viral loads in patients within days of use. However, it is unclear whether the federal government has enough money to make such a purchase as Congress has waffled on additional COVID-19 funding. (Article here)